Skip to main content

Table 4 Cox proportional hazards regression analysis of association between potential factors and death after PPV in the 100 CRPC patients

From: A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time

Factors Cut-offsa Univariate Multivariate
   p value Hazard ratio 95% CI p value Hazard ratio 95% CI
IgG response Positive vs. negative <0.0001 0.19 0.101-0.355 0.001 0.272 0.125-0.592
ECOG performance status 0 vs. 1 <0.0001 0.073 0.031-0.174 0.004 0.179 0.056-0.569
CRP Low (<3000 ng/mL) vs. high 0.012 0.461 0.252-0.842 0.006 0.389 0.199-0.759
PSADT Increase (2 times) vs. no 0.018 0.477 0.258-0.881 0.004 0.357 0.176-0.725
PSA Low (<30 ng/mL) vs. high 0.004 0.407 0.221-0.749 0.008 0.361 0.171-0.762
Prior chemotherapy Untreated vs. treated 0.037 0.536 0.298-0.962 0.329 0.695 0.335-1.445
T-cell response Positive vs. negative 0.039 0.51 0.269-0.967 0.273 0.679 0.340-1.357
>50% PSA decline Positive vs. negative 0.046 0.387 0.152-0.984 0.553 0.733 0.263-2.042
Number of lymphocytes High (>1300/μL) vs. low 0.054 0.562 0.313-1.009 - - -
IL6 Low (<2.4 pg/mL) vs. high 0.057 0.491 0.236-1.021 - - -
Pts. age Low (<69 years) vs. high 0.186 0.666 0.364-1.218 - - -
Gleason score Low (<8) vs. high 0.623 1.162 0.637-2.128 - - -
SAA Low (<8 μg/mL) vs. high 0.709 0.875 0.433-1.767 - - -
  1. Of the 100 men, 64 died.
  2. aLymphocyte, PSA, and patient age are based on median values.
  3. Abbreviations: PPV, personalized peptide vaccination; CRPC, castration-resistant prostate cancer; CI, confidence intervals; ECOG, Eastern Cooperative Oncology Group; PSA, prostate-specific antigen; PSADT, PSA doubling time; CRP, C-reactive protein; SAA, serum amyloid A; IL6, interleukin 6.